Considering all the above facts, we need, first, more case–control studies with specific populations of NAFLD-associated HCC to validate whether circulating adiponectin is higher in patients with than without NAFLD-associated HCC. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.